Manher Joshi
Plus aucun poste en cours
Fortune : 58 234 $ au 30/06/2024
Profil
Manher AJ Joshi worked as Head-US Medical Affairs at Allergan, Inc. He then worked as Vice President-Medical Affairs & Operations at Genzyme Corp.
from 2005 to 2008.
From 2008 to 2010, he worked as SVP-Strategic Development & Medical Operations at Synageva BioPharma Corp.
Most recently, he is working as Chief Medical Officer & Executive Vice President at Atara Biotherapeutics, Inc. starting from 2018 and will continue until 2024.
Joshi completed his undergraduate degree from Boston University and his doctorate from Boston University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 16/11/2023 | 6 851 ( 0,14% ) | 58 234 $ | 30/06/2024 |
Anciens postes connus de Manher Joshi
| Sociétés | Poste | Fin |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 02/02/2024 |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 01/07/2010 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/10/2008 |
| ALLERGAN, INC. | Corporate Officer/Principal | - |
Formation de Manher Joshi
| Boston University School of Medicine | Doctorate Degree |
| Boston University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Allergan, Inc.
 Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
